drug · small molecule
patient view →rilzabrutinib
Marketedupdated 2mo agoby $SNY Sanofi🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for autoimmune thrombocytopenic purpura and 10 investigational indications.
indications
investigational
Sickle Cell Disease
targets
Tyrosine-protein kinase BTK
all catalysts(0)
nothing on the calendar yet
News(1)
- Sanofi MS drug rejected in US gets an endorsement in Europe<figure><div><img src="https://imgproxy.divecdn.com/FBR1IQNmU9Hqatva496Zg2G8JMHsqV0UGsf4LMARqYo/g:nowe:189:144/c:1776:1003/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS80OTY5MDc4Mzc…biopharma_dive · 2mo ago
comments(0)
5-min edit window · permanent after that